Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy
- PMID: 10981666
- DOI: 10.1038/sj.gt.3301249
Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy
Abstract
Humans lacking the ZAP-70 protein tyrosine kinase present with an absence of CD8+ T cells and defective CD4+ T cells in the periphery. This severe combined immunodeficiency is fatal unless treated by allogeneic bone marrow transplantation. However, in the absence of suitable marrow donors, the development of alternative forms of therapy is desirable. Because lymphocytes are long-lived, it is possible that introduction of the wild-type ZAP-70 gene into CD4+ ZAP-70-deficient T cells will restore their immune function in vivo. Initial investigations evaluating the feasibility of gene therapy for ZAP-70 deficiency were performed using HTL V-I-transformed lymphocytes. Although transformation was useful in circumventing problems associated with the maintenance of ZAP-70-deficient T cells and low gene transfer levels, the presence of HTL V-I precluded any biological studies. Here, we investigated a retrovirus-mediated approach for the correction of primary T cells derived from two ZAP-70-deficient patients. Upon introduction of the wild-type ZAP-70 gene, TCR-induced MAPK activation, IL-2 secretion and proliferation were restored to approximately normal levels. Importantly, this gain-of-function was associated with a selective growth advantage of gene-corrected cells, thereby indicating the feasibility of a gene therapy-based strategy.
Similar articles
-
In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.J Clin Invest. 2005 Aug;115(8):2287-95. doi: 10.1172/JCI23966. J Clin Invest. 2005. PMID: 16075064 Free PMC article.
-
An improved retroviral gene transfer technique demonstrates inhibition of CD4-CD8- thymocyte development by kinase-inactive ZAP-70.J Immunol. 1998 Sep 15;161(6):2888-94. J Immunol. 1998. PMID: 9743350
-
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.J Exp Med. 1996 Nov 1;184(5):2031-6. doi: 10.1084/jem.184.5.2031. J Exp Med. 1996. PMID: 8920891 Free PMC article.
-
ZAP-70 and defects of T-cell receptor signaling.Semin Hematol. 1998 Oct;35(4):310-20. Semin Hematol. 1998. PMID: 9801260 Review.
-
The structure, regulation, and function of ZAP-70.Immunol Rev. 2009 Mar;228(1):41-57. doi: 10.1111/j.1600-065X.2008.00753.x. Immunol Rev. 2009. PMID: 19290920 Review.
Cited by
-
ZAP70: a master regulator of adaptive immunity.Semin Immunopathol. 2010 Jun;32(2):107-16. doi: 10.1007/s00281-010-0196-x. Epub 2010 Feb 5. Semin Immunopathol. 2010. PMID: 20135127 Review.
-
Advances of gene therapy for primary immunodeficiencies.F1000Res. 2016 Mar 9;5:F1000 Faculty Rev-310. doi: 10.12688/f1000research.7512.1. eCollection 2016. F1000Res. 2016. PMID: 27508076 Free PMC article. Review.
-
Gene therapy for immunodeficiency.Curr Allergy Asthma Rep. 2001 Sep;1(5):407-15. doi: 10.1007/s11882-001-0025-3. Curr Allergy Asthma Rep. 2001. PMID: 11892066 Review.
-
Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases.Int J Hematol. 2014 Apr;99(4):383-92. doi: 10.1007/s12185-014-1524-z. Epub 2014 Feb 1. Int J Hematol. 2014. PMID: 24488786 Review.
-
In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.J Clin Invest. 2005 Aug;115(8):2287-95. doi: 10.1172/JCI23966. J Clin Invest. 2005. PMID: 16075064 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials